Cargando…

Toll-Like Receptor Agonists Synergize with CD40L to Induce Either Proliferation or Plasma Cell Differentiation of Mouse B Cells

In a classical dogma, pathogens are sensed (via recognition of Pathogen Associated Molecular Patterns (PAMPs)) by innate immune cells that in turn activate adaptive immune cells. However, recent data showed that TLRs (Toll Like Receptors), the most characterized class of Pattern Recognition Receptor...

Descripción completa

Detalles Bibliográficos
Autores principales:	Boeglin, Emmanuelle, Smulski, Cristian R., Brun, Susana, Milosevic, Sara, Schneider, Pascal, Fournel, Sylvie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2011
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3184999/ https://www.ncbi.nlm.nih.gov/pubmed/21991317 http://dx.doi.org/10.1371/journal.pone.0025542

Ejemplares similares

Hetero-oligomerization between the TNF receptor superfamily members CD40, Fas and TRAILR2 modulate CD40 signalling
por: Smulski, Cristian R, et al.
Publicado: (2017)

Synthetic ligands of death receptor 5 display a cell-selective agonistic effect at different oligomerization levels
por: Beyrath, Julien, et al.
Publicado: (2016)

Proimmunogenic impact of MEK inhibition synergizes with agonist anti-CD40 immunostimulatory antibodies in tumor therapy
por: Baumann, Daniel, et al.
Publicado: (2020)

IL-15 synergizes with CD40 agonist antibodies to induce durable immunity against bladder cancer
por: Wong, Jeffrey L., et al.
Publicado: (2023)

IL-15 synergizes with CD40 agonist antibodies to induce durable immunity against bladder cancer
por: Wong, Jeffrey L., et al.
Publicado: (2023)

Whole body irradiation and agonist anti-CD40 synergize to promote adoptive T cell therapy of resistant murine pancreatic neuroendocrine tumors
por: Ward-Kavanagh, Lindsay, et al.
Publicado: (2015)

PARP1-Erk synergism in proliferating cells
por: Visochek, Leonid, et al.
Publicado: (2018)

OX40 agonist immunotherapy expands tumor reactive CD8 T cells with a unique T cell receptor repertoire and synergizes with PDL-1 blockade to promote tumor regression
por: Moran, Amy, et al.
Publicado: (2014)

BAFF and BAFF-Receptor in B Cell Selection and Survival
por: Smulski, Cristian R., et al.
Publicado: (2018)

Activation of human B cells by the agonist CD40 antibody CP-870,893 and augmentation with simultaneous toll-like receptor 9 stimulation
por: Carpenter, Erica L, et al.
Publicado: (2009)

SUMOylation inhibitors synergize with FXR agonists in combating liver fibrosis
por: Zhou, Jiyu, et al.
Publicado: (2020)

CD40 Signaling Synergizes with TLR-2 in the BCR Independent Activation of Resting B Cells
por: Jain, Shweta, et al.
Publicado: (2011)

PKC agonism restricts innate immune suppression, promotes antigen cross-presentation and synergizes with agonistic CD40 antibody therapy to activate CD8(+) T cells in breast cancer
por: Chaib, Mehdi, et al.
Publicado: (2022)

Nanoparticle-Delivered Multimeric Soluble CD40L DNA Combined with Toll-Like Receptor Agonists as a Treatment for Melanoma
por: Stone, Geoffrey W., et al.
Publicado: (2009)

TLR2/6 agonists and IFNγ synergize to induce melanoma cells to produce T-cell recruiting chemokines
por: Mauldin, Ileana S, et al.
Publicado: (2013)

Toll-Like Receptor 9 Agonists in Cancer
por: Karapetyan, Lilit, et al.
Publicado: (2020)

Natural toll-like receptor agonists in prophylactic vaccines for dendritic cell activation
por: Peng, Paul, et al.
Publicado: (2015)

The functional and inflammatory response of brain endothelial cells to Toll-Like Receptor agonists
por: Johnson, Rebecca H., et al.
Publicado: (2018)

Toll-Like Receptor Agonists Modulate Wound Regeneration in Airway Epithelial Cells
por: Lewandowska-Polak, Anna, et al.
Publicado: (2018)

No Evidence That Soluble TACI Induces Signalling via Membrane-Expressed BAFF and APRIL in Myeloid Cells
por: Nys, Josquin, et al.
Publicado: (2013)

Intratumoral immune activation with TLR4 agonist synergizes with effector T cells to eradicate established murine tumors
por: Albershardt, Tina C., et al.
Publicado: (2020)

Effects of the combination of a monoclonal agonistic mouse anti-OX40 antibody and toll-like receptor agonists: Unmethylated CpG and LPS on an MB49 bladder cancer cell line in a mouse model
por: Gulyás, Dominik, et al.
Publicado: (2022)

Activation of Dendritic Cells by the Novel Toll-Like Receptor 3 Agonist RGC100
por: Naumann, Kai, et al.
Publicado: (2013)

Toll-Like Receptor 9 Agonists for Cancer Therapy
por: Melisi, Davide, et al.
Publicado: (2014)

Toll-Like Receptor Agonists as Adjuvants for Allergen Immunotherapy
por: Kirtland, Max E., et al.
Publicado: (2020)

Applications and clinical trial landscape using Toll-like receptor agonists to reduce the toll of cancer
por: Rolfo, Christian, et al.
Publicado: (2023)

Toll-Like Receptor Ligands and Interferon-γ Synergize for Induction of Antitumor M1 Macrophages
por: Müller, Elisabeth, et al.
Publicado: (2017)

Preconditioning of Rat Bone Marrow-Derived Mesenchymal Stromal Cells with Toll-Like Receptor Agonists
por: Evaristo-Mendonça, Fabiana, et al.
Publicado: (2019)

Toll-like receptor-agonist-based therapies for respiratory viral diseases: thinking outside the cell
por: Girkin, Jason L.N., et al.
Publicado: (2022)

Intravenous injection of a modified vaccinia ankara virus induces intratumoral CD8+ lymphocyte infiltration favoring tumor control in an orthotopic tumor model upon combinatorial treatment with a TLR9 agonist
por: Fend, Laetitia, et al.
Publicado: (2014)

Cell Cycle and Anti-Estrogen Effects Synergize to Regulate Cell Proliferation and ER Target Gene Expression
por: Dalvai, Mathieu, et al.
Publicado: (2010)

Relationship between the agonist activity of synthetic ligands of TRAIL-R2 and their cell surface binding modes
por: Chekkat, Neila, et al.
Publicado: (2018)

Synergic Activation of Toll-Like Receptor (TLR) 2/6 and 9 in Response to Ureaplasma parvum & urealyticum in Human Amniotic Epithelial Cells
por: Triantafilou, Martha, et al.
Publicado: (2013)

Agonistic CD40 Antibodies in Cancer Treatment
por: Djureinovic, Dijana, et al.
Publicado: (2021)

The Toll-Like Receptor Agonist Imiquimod Is Active against Prions
por: Oumata, Nassima, et al.
Publicado: (2013)

Trial Watch: Toll-like receptor agonists for cancer therapy
por: Vacchelli, Erika, et al.
Publicado: (2013)

Trial Watch: Toll-like receptor agonists in oncological indications
por: Aranda, Fernando, et al.
Publicado: (2014)

Anti-tumor Activity of Toll-Like Receptor 7 Agonists
por: Chi, Huju, et al.
Publicado: (2017)

The Role of Toll-like Receptor Agonists and Their Nanomedicines for Tumor Immunotherapy
por: Huang, Lingling, et al.
Publicado: (2022)

CD40 agonist-induced IL-12p40 potentiates hepatotoxicity
por: Bonnans, Caroline, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_jm6ft6jgkh9mkkq372k9nfjsf1